Insights

Gathering insights about Minds…

Similar companies to Minds

Minds Tech Stack

Minds uses 8 technology products and services including Docker, Cloudflare CDN, GitLab CI, and more. Explore Minds's tech stack below.

Docker
Containerization
Cloudflare CDN
Content Delivery Network
GitLab CI
Continuous Integration
MongoDB
Database
Google Font API
Font Scripts
Socket.io
Javascript Frameworks
Angular
Javascript Frameworks
Kibana
Search Engines

Media & News

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer.
Dec 09, 2024 | www.prnewswire.com
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
Nov 13, 2024 | www.fool.com
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Nov 06, 2024 | www.prnewswire.com
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
Nov 04, 2024 | www.globenewswire.com
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform targets serotonin regulation, aiming to create selective therapies with fewer side effects. DRUG's recent $35 million private placement funds Phase 2 trials, enhancing its financial outlook and potential for significant revenue if BMB-101 is successful.
Oct 30, 2024 | seekingalpha.com
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial.
Oct 28, 2024 | www.businesswire.com
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Oct 21, 2024 | www.globenewswire.com

Minds's Email Address Formats

Minds uses at least 1 format(s):

Minds Email Formats	Example	Percentage
First@minds.com	John@minds.com	46%
Last@minds.com	Doe@minds.com	5%
First.Last@minds.com	John.Doe@minds.com	3%
First@minds.com	John@minds.com	46%

Frequently Asked Questions

Where is Minds's headquarters located?

Minds's main headquarters is located at PO Box 7681 Wilton, CT 06897 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Minds's stock symbol?

Minds is a publicly traded company; the company's stock symbol is DRUG.

What is Minds's official website and social media links?

Minds's official website is minds.com and has social profiles on LinkedIn.

How much revenue does Minds generate?

As of October 2024, Minds's annual revenue reached $3.8M.

What is Minds's NAICS code?

Minds's NAICS code is 5112 - Software Publishers.

How many employees does Minds have currently?

As of October 2024, Minds has approximately 154 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: B. O.Chief Executive Officer: B. O.Chief Technology Officer: M. H.. Explore Minds's employee directory with LeadIQ.

What industry does Minds belong to?

Minds operates in the Software Development industry.

What technology does Minds use?

Minds's tech stack includes DockerCloudflare CDNGitLab CIMongoDBGoogle Font APISocket.ioAngularKibana.

What is Minds's email format?

Minds's email format typically follows the pattern of . Find more Minds email formats with LeadIQ.

How much funding has Minds raised to date?

As of October 2024, Minds has raised $10M in funding. The last funding round occurred on Jun 15, 2021 for $10M.

When was Minds founded?

Minds was founded in 2011.

Minds

Software DevelopmentConnecticut, United States51-200 Employees

Minds is open source and decentralized social networking software. We build social apps in minutes for brands, creators and organizations who want more ownership of their community spaces online. Our flagship social network Minds.com has grown to over 5 million members who are passionate about Internet freedom and digital rights.

Company Overview

Headquarters: PO Box 7681 Wilton, CT 06897 US
Website: minds.com
Stock Symbol: DRUG
NAICS Code: 5112 - Software Publishers
Founded: 2011
Employees: 51-200

Media & News

Funding & Financials

$10M
Minds has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Jun 15, 2021 in the amount of $10M.
$10M
Minds's revenue is in the range of $10M

Funding & Financials

$10M
Minds has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Jun 15, 2021 in the amount of $10M.
$10M
Minds's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Minds

Twitter

Telegram

Ello

Mastodon

Minds

Rumble

MeWe

LinkedIn

Diaspora

Parler

Steemit

Minds Tech Stack

Media & News

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Minds's Email Address Formats

Frequently Asked Questions

Where is Minds's headquarters located?

What is Minds's stock symbol?

What is Minds's official website and social media links?

How much revenue does Minds generate?

What is Minds's NAICS code?

How many employees does Minds have currently?

What industry does Minds belong to?

What technology does Minds use?

What is Minds's email format?

How much funding has Minds raised to date?

When was Minds founded?

Minds

Company Overview

Media & News

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?